Navigation Links
RRD Selected as Development Partner for NIH Therapeutics for Rare and Neglected Diseases Program
Date:1/24/2011

tructure.  The DevCo® model creates external product development companies where investment is in asset optimization rather than traditional infrastructure.  For more information visit www.rrdintl.com.  RRD International: Accelerating the Right Development; Creating Lasting Value.

About TRND

The National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program, http://trnd.nih.gov is a congressionally mandated program to encourage and speed the development of new drugs for rare and neglected diseases.  This unique program creates a drug development pipeline within the NIH and is specifically intended to stimulate research collaborations with academic scientists, non-profit organizations, and pharmaceutical and biotechnology companies working on rare and neglected illnesses.  The TRND program provides an opportunity to partner with, and gain access to, drug development scientific capabilities, expertise, and resources in a collaborative environment with the goal of moving promising therapeutics into clinical testing.


'/>"/>
SOURCE RRD International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
2. CSA Medical Selected to Present at Mid-Atlantic Bio Conference
3. PMC BioTec Selected as a GoingGreen Silicon Valley 100 Winner
4. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
5. Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility
6. Ion Torrent Selected as World Economic Forum Technology Pioneer
7. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
8. Genedata Phylosopher Selected for ERA-NET sncRNA Project
9. NeoStem Selected to Present at American Society for Apheresis
10. DNA Genoteks Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project
11. OrthoAccel Technologies, Inc. Selected to Pitch at the 2010 WBTshowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... yet often overlooked factor in the medical application ... of aggregation on both radiofrequency heating and magnetic ... nanoparticles (IONPs), including detailed analysis of the aggregate ... shown to produce significant reductions in both heating ... method to quantify and correlate these effects for ...
(Date:9/2/2014)... , September 2, 2014 Persistence ... Membrane Technology in Pharmaceutical, Biopharma and Life Sciences: ... by 2019" the global membrane technology market for pharmaceutical, biopharma and ... 2014 and is expected to grow at a CAGR ... estimated value of USD 10,886.0 million in 2019. ...
(Date:9/2/2014)... 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... and Trademark Office (PTO) has issued a patent related ... weight loss. NB32 is a fixed-dose combination of naltrexone ... Patent No. 8,815,889 claims methods for treating insulin resistance ... expires in 2024. If NB32 is approved for use ...
(Date:9/2/2014)... Rocky Mount, NC (PRWEB) September 02, 2014 ... the establishment of its 11th clinical research site: PMG ... has assumed ownership and operation of the clinical research ... NC, further expanding PMG’s presence in eastern North Carolina. ... 130,000 patients. For the patients in Rocky Mount and ...
Breaking Biology Technology:Accounting for biological aggregation in heating and imaging of magnetic nanoparticles 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... HIGHLIGHTS:2010 Results (all percentages are to comparable periods in 2009) ... a new quarterly high. Q4 sales grew by 2% and 3% ... sales increased 6% and 5% on a reported and currency adjusted ... was $0.76. Excluding restructuring costs of $0.07, adjusted Q4 2010 diluted ...
... new type of biological and chemical sensor that has few ... long-lasting. The "diffraction-based" sensors are made of thin stripes ... contracts depending on the acidity of its environment. Recent ... to precisely determine pH - a measure of how acidic ...
... RATON, Fla., Feb. 8, 2011 Stem Cell Assurance, ... engagement of Marcum LLP to audit its financial statements as ... then ended.  Ranked 15th among the "Top 25 Firms" by ... more than 1,100 professionals, including more than 150 partners, in ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13Hydrogels used to make precise new sensor 2Hydrogels used to make precise new sensor 3Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors 2
(Date:9/2/2014)... [Brown University] It,s hard to comprehend how bad ... has become without knowing what it was before people ... rate was 10 times lower than scientists had thought, ... worse. , Extinctions are about 1,000 times more frequent ... came along. The explanation from lead author Jurriaan de ...
(Date:9/2/2014)... that professional baseball pitchers with poor core stability are more ... season because of injury than are pitchers who have good ... In the study, 347 pitchers were assessed for lumbopelvic control ... as they raised a leg to step up were up ... days cumulative, not consecutive during the season than ...
(Date:9/2/2014)... led by researchers at the University of Warwick in ... just published in the Journal Early Human Development ... spent in hospital after birth and the use of ... in preterm children. , Mathematic abilities are crucial for ... in very preterm children. Earlier studies of children who ...
Breaking Biology News(10 mins):Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Mechanical ventilation a key indicator for pre-term children's math problems 2
... detection techniques developed at the University, the team mapped ... and developed a model of their likely distribution as ... action is needed. University of Canberra professor in ... found foxes are widespread in northern and eastern Tasmania ...
... University of Southampton has shown that copper can ... to the increasing number of antibiotic-resistant infections worldwide. ... largely responsible for the development of antibiotic-resistance, which ... healthcare-associated infections (HCAIs). The newly-published paper, which ...
... Institution are rolling out results from the new Airborne ... at the American Geophysical Union (AGU) meetings in San ... uncovering a previously invisible ecological world. To watch a ... the world in a whole new way, click here. ...
Cached Biology News:Fox invasion threatens wave of extinction, UC research finds 2New study shows how copper restricts the spread of global antibiotic-resistant infections 2Carnegie debuts revolutionary biosphere mapping capability at AGU 2Carnegie debuts revolutionary biosphere mapping capability at AGU 3
... unique human proteins on a 1x3 ... a cross section of all cellular ... high-quality results. Additional control proteins and ... validity and reproducibility., ,UNIchip protein microarrays ...
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, all ... Ontology classification, are arrayed in quadruplicate ... and a specific chip layout guarantee ...
... The Sub-Plates are E.Coli glycerol stocks ... well contains 50 cDNA clones with approximately ... of the a master plate well, the ... 96-well PCR to identify the positive well(s). ...
... The TNT Coupled Reticulocyte Lysate ... eukaryotic in vitro translations: a single-tube, ... Systems greatly simplify the process and ... in vitro translation results. Standard rabbit ...
Biology Products: